Cynata Therapeutics is a topic within the NeuroWiki knowledge base covering aspects of neurodegenerative disease research and mechanisms. [1]
Cynata Therapeutics Limited is an Australian biotechnology company specializing in cell therapy and regenerative medicine, with a focus on developing treatments for neurodegenerative diseases including Parkinson's disease. [2]
| Attribute | Value | [3]
|-----------|-------|
| Founded | 2008 (as Cynata Pty Ltd) |
| Headquarters | Melbourne, Australia |
| Ticker | ASX: CYP |
| CEO | Dr. Ross Macdonald |
| Market Cap | ~0M AUD |
Cynata's core technology is its induced Mesenchymal Stem Cell (iMSC) platform:
| Drug | Mechanism | Stage | Notes |
|---|---|---|---|
| CYP-001 | iMSC therapy | Phase 1 | First-in-human study |
The CYP-001 program aims to provide neuroprotective effects through MSC-mediated immunomodulation and paracrine signaling.
Cynata's Phase 1 trial for Parkinson's disease represents a novel cell therapy approach:
Cynata was founded based on technology from the University of Melbourne and developed its iMSC platform through academic collaborations. The company went public on the ASX in 2015.